Author: Sara Savelli ; Luigi Irace ; Luciano Izzo ; Bruno Gossetti ; Roberto Gattuso ; Ombretta Martinelli ; Fabrizio Benedetti-Valentini ; Fabrizia Giannoni ; Rita Massa

AbstractBackgroundCarotid body tumours (CBTs) are very rare lesions which should be treated as soon as possible even when benign since small tumour size permits easier removal and lower incidence of perioperative complications and recurrence. Malignant forms are rare and they can be identified by lymph node invasion and metastases in distant locations. The need of reliable and effective diagnostic modalities for both primary CBTs and its metastases or recurrence is evident.The present study reviews our experience and attempt to define the role of colour coded ultrasound (CCU) and Somatostatin receptor scintigraphy (SRS) with Indium-111-DTPA-pentetretide (Octreoscan®) using both planar and single photon emission tomography (SPECT) technique in the diagnosis and follow-up of these uncommon lesions within a multidisciplinary approach.MethodsFrom 1997 to 2008, 12 patients suffering from 16 CBTs (4 bilateral) were investigated by CCU and SRS-SPECT before and after surgery. All tumours were grouped according to Shamblin's classification in order to assess the technical difficulties and morbidity of surgical resection on the ground of their size and relationship with the carotid arteries. Intraoperative radiocaptation by Octreoscan®) was also carried out in all cases to evaluate the radicality of surgery. All perioperative scans were evaluated by the same nuclear medicine physician.ResultsPreoperatively CCU showed CBTs (four were not palpable) with a sensitivity of 100%. Radioisotope imaging identified the CBTs as chemodectomas in 15 cases while no radioisotopic uptake was detected in 1 vagus nerve neurinoma. No evidence of metastasis or multicentricity were seen by total body radioisotopic scans. Combined data from CCU and SRS-SPECT allowed to determine tumour size in order to select 7 larger tumours which were submitted to selective preoperative embolization.Intraoperatively Octreoscan demonstrated microscopic tumour leftovers promptly removed in 1 case and an unresectable remnant at the base of the skull in another case.During follow-up CCI and radioisotope scans showed no recurrence in 14 cases and a slightly enlargement of the intracranial residual as detected during surgery in 1 patient.ConclusionCCU may allow an early and noninvasive detection of CBTs and hence safer operations. The combined use of CCU and SRS-SPECT provide useful data to identify those tumours and to evaluate their extent and carotid arteries infiltration. Radioisotope imaging is a sensitive modality to detect metastases and lymph node involvement that are markers of CBT malignancy. After surgery CCU and SRS-SPECT can be accurate modalities for surveillance for an early detection of CBTs recurrence.

01 Dec 1995·Clinical EndocrinologyQ2 · MEDICINE

Successful localization of an occult ACTH‐secreting bronchial carcinoid tumour with ¹¹¹indium‐DTPA labelled octreotide

Q2 · MEDICINE

Article

Author: Kaskarelis J ; Giannakenas C ; Belenis I ; Platis O ; Tsagarakis S ; Vassilakos Pj ; Rontoyianni D ; Thalassinos N

SummaryEctopic ACTH secretion due to occult carcinoid tumours is an occasional cause of ACTH dependent Cushing's syndrome. In many cases the ectopic source may be obvious, but sometimes no obvious source is evident, the so‐called occult ectopic syndrome. Due to their small size, localization of such occult tumours, particularly bronchial carcinoids, may be extremely difficult. Whole body CT and verious sampling studies have been used but are not always successful in determining the site of such lesions. We report a 40‐year‐old patient with the ectopic ACTH syndrome due to a 0.6‐cm bronchial carcinoid tumour which was successfully localized by 111indium‐DTPA labelled octreotide scintigraphy.

01 May 1993·Annals of the New York Academy of SciencesQ2 · CROSS-FIELD

[¹¹¹In]DTPA‐Labeled Analogues of α‐MSH for the Detection of MSH Receptors In Vitro and In Vivo

Q2 · CROSS-FIELD

Article

Author: B. Stolz ; A. N. Eberle ; C. Bruns ; J. Pless ; C. Bagutti ; R. Albert

[¹¹¹In]DTPA-bis-([Nle⁴,Asp⁵,D-Phe⁷,Lys¹⁰]α-MSH_4-10) and [¹¹¹In]DTPA-bis-([Nle⁴,Asp⁵,D-Phe⁷,Lys(bis-DHP)¹⁰]α-MSH_4-10) when administered to control and melanoma-bearing mice showed a relatively high accumulation in liver and were excreted mainly via the kidneys, and both were potent and specific radioligands for MSH receptors in the melanomas.

100 Deals associated with Indium In-111 Pentetate Disodium

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DBSALT002473

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis